British clinicians have studied the side effects of the first venous administration of biphosphonates to combat osteoporosis:
- the records of 107 children who had received biphosphonates for inflammatory or genetic diseases (including Duchenne muscular dystrophy or DMD) were analysed retrospectively,
- the frequency of immediate complications and the length of hospitalisation were taken into account,
- in most cases, these adverse events were minor and no longer warranted a 24-hour admission for observation,
- however, certain groups remain at risk (such as DMD with severe cortico-induced osteoporosis) and require increased vigilance.